JPRN-UMIN000009924已完成未知
A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiography - A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiography
Showa University Northern Hospital0 个研究点目标入组 100 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)history of allergy against this drug or similar compounds (2)anuria (urine volume <100ml/day) (3)subjects who cannot feel thirsty or have difficulty to drink (4)subjects whose serum sodium level is over 147mEq/L (5)subjects who are pregnant or possibly pregnant (6)subjects who already have tolvaptan at the entry (7)acute coronary syndrome (8)patients who are judged to be inappropriate to this study
研究者
相似试验
已完成
Unknown
A study to evaluate the dose-response efficacy of body fat reduction by continuous ingestion of test food. (SWE-2023-07-HCRINK)ot applicableJPRN-UMIN000051748Suntory Wellness Limited200
进行中（未招募）
不适用
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-ESaboratorios Dr. Esteve, SA450
进行中（未招募）
1 期
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-CZaboratorios Dr. Esteve, SA450
已完成
2 期
The Study of Dose Response Relationship Evaluation of AryoSeven in Hemophilia PatientsCondition 1: Congenital Hemophilia A with inhibitors. Condition 2: Congenital Hemophilia B with inhibitors.Hereditary factor VIII deficiencyHereditary factor IX deficiencyIRCT20161202031193N3AryoGen Pharmed12
终止
2 期
To identify the effective dose(s) of RT234 (vardenafil inhalation powder) to acutely improve pulmonary vascular haemodynamics in study participants with Pulmonary Arterial Hypertension (PAH).Cardiovascular - Other cardiovascular diseasesPulmonary Arterial HypertensionACTRN12619001178134Respira Therapeutics Australia Pty Ltd14